Based on the first interim analysis of the phase III KEYNOTE-826 study (21), pembrolizumab combined with platinum-based chemotherapy ± bevacizumab was approved as first-line treatment for patients with PD-L1- positive persistent cervical cancer or r/mCC (CPS ≥ 1). This evidence concerns the gene CD274 and cervical carcinoma.